Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,400 shares of common stock to
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 7, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart , M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco , as an independent director to its
- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from more than five years of maralixibat treatment across three Phase 2 ALGS studies
- Integrated safety analysis on gastrointestinal tolerability of maralixibat in patients with Alagille syndrome presented in poster session. - Five-year analysis demonstrating improvements in transplant-free survival for patients with PFIC2 featured in oral presentation; abstract nominated for the